Výsledky vyhledávání

Akademický článek

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX-02 in Healthy Subjects.

Autor: Leubitz A; Eloxx Pharmaceuticals, Inc, Waltham, Massachusetts, USA., Vanhoutte F; SGS Life Sciences, Clinical Pharmacology Unit, Antwerp, Belgium., Hu MY; Eloxx Pharmaceuticals, Inc, Waltham, Massachusetts, USA., Porter K; Consultant to Eloxx Pharmaceuticals, Inc, Waltham, Massachusetts, USA., Gordon E; Eloxx Pharmaceuticals, Inc, Waltham, Massachusetts, USA., Tencer K; Eloxx Pharmaceuticals, Inc, Waltham, Massachusetts, USA., Campbell K; Consultant to Eloxx Pharmaceuticals, Inc, Waltham, Massachusetts, USA., Banks K; Eloxx Pharmaceuticals, Inc, Waltham, Massachusetts, USA., Haverty T; Eloxx Pharmaceuticals, Inc, Waltham, Massachusetts, USA.

Publikováno v: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Aug; Vol. 10 (8), pp. 859-869. Date of Electronic Publication: 2021 Jan 19.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX-02 in Patients With Nephropathic Cystinosis.

Autor: Haverty T; Eloxx Pharmaceuticals, Waltham, Massachusetts, USA., Wyatt DJ; Syneos Health, Miami, Florida, USA., Porter KM; Pharmacokinetics Consultant, Eloxx Pharmaceuticals, Waltham, Massachusetts, USA., Leubitz A; Eloxx Pharmaceuticals, Waltham, Massachusetts, USA., Banks K; Eloxx Pharmaceuticals, Waltham, Massachusetts, USA., Goodyer P; McGill University, Montreal, Quebec, Canada., Hu MY; Eloxx Pharmaceuticals, Waltham, Massachusetts, USA.

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2021 Jul; Vol. 61 (7), pp. 923-931. Date of Electronic Publication: 2021 Jan 18.

Zobrazit plný text záznamu

Akademický článek

P251 ELX-02 pharmacokinetic profile appropriate for cystic fibrosis patient use

Autor: Aggarwal, A., Sharpe, N., Leubitz, A., Maier, G., Haverty, T., Williams, G.

Publikováno v: In Journal of Cystic Fibrosis June 2019 18 Supplement 1:S128-S128

Zobrazit plný text záznamu

Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection

Autor: J. Charette, Julie A. Auger, Haverty T, Jeffrey A. Bluestone, E. S. Woodle, Donna Peace, Thistlethwaite, R. A. Zivin, O'Laughlin R, Xu D, Jollife Lk

Publikováno v: Transplantation. 68(5)

Background HuOKT3gamma1(Ala-Ala) is a genetically-engineered derivative of the parental murine OKT3 monoclonal antibody, in which the six complementarity-determining regions have been grafted within a human IgG1 mAb, and whose C(H)2 region has been a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a7ae0b6474308f917bb42156d8a1785
https://pubmed.ncbi.nlm.nih.gov/10507477

Zobrazit plný text záznamu

Akademický článek

Cystinosis — a review of disease pathogenesis, management, and future treatment options.

Autor: Devitt, Lauren¹ ldevitt@tcd.ie

Publikováno v: Journal of Rare Diseases. 6/10/2024, Vol. 3 Issue 1, p1-12. 12p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Unveiling Selected Influences on Chronic Kidney Disease Development and Progression.

Autor: Fularski, Piotr¹ (AUTHOR) magdalena.gasior@stud.umed.lodz.pl, Czarnik, Witold¹ (AUTHOR), Frankenstein, Hanna¹ (AUTHOR), Gąsior, Magdalena¹ (AUTHOR), Młynarska, Ewelina¹ (AUTHOR) emmlynarska@gmail.com, Rysz, Jacek² (AUTHOR), Franczyk, Beata¹ (AUTHOR)

Publikováno v: Cells (2073-4409). May2024, Vol. 13 Issue 9, p751. 18p.

Zobrazit plný text záznamu

Plný text ve formátu HTML